Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Malaria transmission blocking compounds: a patent review53
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities45
FAK inhibitors in cancer, a patent review – an update on progress36
Recent developments of agents targeting Vibrio cholerae : patents and literature data35
The role of patent analysis in target selection33
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)32
Update on mGlu4 modulator patents: 2017 to present31
Mucormycosis medications: a patent review30
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature29
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)28
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)28
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present27
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)26
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review24
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)23
Caspase inhibitors: a review on recently patented compounds (2016–2023)23
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
An updated patent review of AKT inhibitors (2020 – present)22
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)21
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)21
Inhibition of GTPase KRAS G12D : a review of patent literature21
A patent review of MAPK inhibitors (2018 – present)21
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
PDE1 inhibitors: a review of the recent patent literature (2008-present)21
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
Antiprotozoal drugs: challenges and opportunities19
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)19
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)18
Small-molecule RNA ligands: a patent review (2018–2024)17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)17
An updated patent review of MALT1 inhibitors (2021–present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)16
A patent review of IDH1 inhibitors (2018-present)16
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
An updated patent review on PD-1/PD-L1 antagonists (2022-present)16
A patent and literature review of CDK12 inhibitors14
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
Biofilm and bacterial membrane vesicles: recent advances13
An updated patent review of EZH2 inhibitors (2024–present)13
Antimalarial drugs: what’s new in the patents?13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)13
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)13
Dopamine D3 receptor ligands: a patent review (2014–2020)13
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Are patents important indicators of innovation for Chagas disease treatment?12
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
Ferroportin-inhibitor salt: patent evaluation WO201819297312
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
The patent review of the biological activity of tropane containing compounds11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
A patent review of mTOR inhibitors for cancer therapy (2011–2020)10
Correction10
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
An updated patent review of TRPA1 antagonists (2020 – present)10
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)10
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages10
A patent review of selective CDK9 inhibitors in treating cancer10
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)9
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)9
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)9
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress9
A patent review of BRD4 inhibitors (2020–present)9
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)8
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)8
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)8
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
A patent review of CXCR7 modulators (2019-present)8
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)8
Patent landscape of small molecule inhibitors of METTL3 (2020-present)8
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)7
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20237
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update7
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid7
Therapeutic cysteine protease inhibitors: a patent review (2018–present)7
An updated patent review on monoamine oxidase (MAO) inhibitors7
A patent perspective of antiangiogenic agents7
A patent review of glutaminyl cyclase inhibitors (2004–present)7
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)6
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)6
A patent review of xanthine oxidase inhibitors (2021–present)6
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)6
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents6
Recent advances in the development of STING inhibitors: an updated patent review6
An updated patent review of Mcl-1 inhibitors (2020–2022)6
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective6
Pitfalls in patenting academic CAR-T cells therapy6
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)6
An updated patent review of glutaminase inhibitors (2019–2022)5
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)5
A patent review of IDO1 inhibitors for cancer (2023 – present): an update5
An updated patent review of stimulator of interferon genes agonists (2021 – present)5
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)5
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)5
Natural products as a source of new anticancer chemotypes5
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)5
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature5
Proteasome inhibitors as anticancer agents5
Anticancer drugs: where are we now?5
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present5
Recent updates on Wnt signaling modulators: a patent review (2014-2020)5
An updated patent review of BRD4 degraders5
Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 20215
A review of the patent literature surrounding TRPV1 modulators5
Update on JNK inhibitor patents: 2015 to present4
PIM kinase inhibitors: an updated patent review (2016-present)4
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)4
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections4
CBL-B – An upcoming immune-oncology target4
An updated patent review of IDO1 inhibitors for cancer (2018–2022)4
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review4
Targeting the TGF-β signaling pathway: an updated patent review (2021–present)4
Factor IX(a) inhibitors: an updated patent review (2003-present)4
Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)4
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)4
BET inhibitors: an updated patent review (2018–2021)4
A patent review of adenosine A2Breceptor antagonists (2016-present)4
Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)4
Malaria vaccines4
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present)4
MEK inhibitors in oncology: a patent review and update (2016 – present)4
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)4
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326154
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)4
CDC7 kinase inhibitors: a survey of recent patent literature (2017–2022)4
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective4
An updated patent review of SOS1 inhibitors (2022–present)4
Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)4
Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)4
0.36620688438416